ALPL and myeloid sarcoma: We found that PPA (adjusted difference: −0.49 [95% CI: −0.68 to −0.3], p = 2.73E-07), PPA/phenylalanine ratio (adjusted difference: −0.41 [95% CI: −0.61 to −0.22], p = 2.97E-05), HPPA (adjusted difference: −0.61 [95% CI: −0.8 to −0.41], p = 1.24E-09) and HPPA/tyrosine ratio (adjusted difference: −0.5 [95% CI: −0.7 to −0.3], p = 1.03E-06) were all significantly decreased in people with MS compared to HCs (Fig. 2e).